L.A. McKeown

News Conference News EuroPCR 2026 Panelists at EuroPCR agreed that with appropriate lesion and patient selection, BRS may be poised to enter a post-Absorb era. PARIS, France—A thinner-strut sirolimus-eluting bioresorbable scaffold (BRS) shows long-term results comparable to those achieved with contemporary DES for the treatment of noncomplex coronary lesions, according to additional follow-up from the FUTURE-II trial.

Adverse pregnancy outcomes were linked to higher BP, BMI, and other cardiometabolic risk factors in kids 20 years later. Adverse pregnancy outcomes that increase future CVD risk reverberate beyond maternal health, according to a longitudinal study of mother-child pairs. The research suggests the impact on their offspring is already apparent by the time the children reach their early 20s.

Only 50% had optimal BP and HbA1c levels and fewer than one in three patients were within recommended lipid control targets. Despite the availability of effective pharmacotherapies, secondary prevention targets are infrequently met in patients in the United States who have had an MI, according to an analysis of National Health and Nutrition Examination Survey (NHANES) data.